Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD
A new analysis finds that men with prostate cancer treated with abiraterone acetate have a significantly higher mortality if they also have preexisting cardiovascular disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 6, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Zytiga May Up Mortality Risk in Prostate Cancer Patients With CVD
(MedPage Today) -- Increased hospitalizations seen among all abiraterone-treated patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 27, 2019 Category: Hematology Source Type: news

J & J Raises U.S. Prices on Around Two Dozen Drugs J & J Raises U.S. Prices on Around Two Dozen Drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara (ustekinumab), prostate cancer drug Zytiga (abiraterone) and blood thinner Xarelto (rivaroxaban), all among its top-selling products.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

J & amp;J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & J raises U.S. prices on around two dozen drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. (Source: Reuters: Health)
Source: Reuters: Health - January 11, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. appeals court declines J & J bid to stop generic Zytiga sales
A U.S. appeals court on Wednesday declined a request by Johnson& Johnson for an temporary restraining order blocking sales of generic versions of its cancer drug Zytiga from hitting the U.S. market. (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Court Issues Ruling in ZYTIGA ® Patent Infringement Litigation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 27, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson edges past profit estimates, lifts outlook
Johnson& Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson profit beats, lifts forecast on cancer drug demand
Johnson& Johnson on Tuesday reported quarterly profit above estimates and raised its full-year forecast, as demand for its cancer drugs Zytiga and Imbruvica helped offset decline in sales of blockbuster drug, Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson profit beat fueled by strength in pharma business
Johnson& Johnson topped analysts' estimates for quarterly profit and revenue on Tuesday, as strong demand for cancer drugs Zytiga and Darzalex more than made up for declining sales of blockbuster treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Yonsa (Abiraterone Acetate Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 7, 2018 Category: Drugs & Pharmacology Source Type: news

Sun Pharma Announces FDA Approval of Yonsa (abiraterone acetate) to Treat Metastatic Castration-Resistant Prostate Cancer
MUMBAI& PRINCETON, N.J.& KING OF PRUSSIA, Pa. May 23, 2018 --(BUSINESS WIRE)--Sun Pharmaceutical Industries Ltd. and includes its subsidiaries and/or associate companies) and Churchill Pharmaceuticals, LLC. (Churchill) today announced that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 23, 2018 Category: Drugs & Pharmacology Source Type: news

Low-Dose Prostate Drug Can Match Standard Dose, Cut Costs Low-Dose Prostate Drug Can Match Standard Dose, Cut Costs
Patients who cannot afford to take abiraterone acetate for metastatic castration-resistant prostate cancer could benefit just as much from taking just a quarter dose with food, say US researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Prostate cancer: How a full stomach could improve treatment
A new study finds that the prostate cancer drug Zytiga is more effective, as well as cheaper, when taken with food, as opposed to on an empty stomach. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 2, 2018 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Full English could make prostate cancer treatment more effective
Current NHS guidelines for the drug abiraterone - also known as Zytiga - say it must be taken on an empty stomach. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2018 Category: Consumer Health News Source Type: news

Full English breakfast could make prostate cancer treatment more effective
Current NHS guidelines for the drug abiraterone - also known as Zytiga - say it must be taken on an empty stomach. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2018 Category: Consumer Health News Source Type: news

Low - Dose Abiraterone Acetate Noninferior for Prostate Cancer
Low - dose AA with low - fat breakfast had greater effect on PSA; similar effect to standard dose (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 29, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Journal, Source Type: news

Low-Dose Abiraterone Acetate Noninferior for Prostate Cancer
WEDNESDAY, March 28, 2018 -- For castration-resistant prostate cancer (CRPC), low-dose abiraterone acetate (AA) with a low-fat breakfast is noninferior to standard dose with fasting in terms of the mean change in prostate-specific antigen (PSA),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2018 Category: Pharmaceuticals Source Type: news

A Light Breakfast Might Cut Cost of Pricey Prostate Cancer Drug, #Zytiga (#Abiraterone Acetate)
WEDNESDAY, March 28, 2018 -- Here's one way to cut the cost of a $10,000-a-month prostate cancer drug: Take it with food, some researchers suggest. Investigators said they found that taking Zytiga (abiraterone acetate) with a low-fat breakfast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2018 Category: General Medicine Source Type: news

A Light Breakfast Might Cut Cost of Pricey Prostate Cancer Drug Zytiga
WEDNESDAY, March 28, 2018 -- Here's one way to cut the cost of a $10,000-a-month prostate cancer drug: Take it with food, some researchers suggest. Investigators said they found that taking Zytiga (abiraterone acetate) with a low-fat breakfast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2018 Category: General Medicine Source Type: news

A Light Breakfast Might Cut Cost of Pricey Prostate Cancer Drug, Zytiga (Abiraterone Acetate)
WEDNESDAY, March 28, 2018 -- Here's one way to cut the cost of a $10,000-a-month prostate cancer drug: Take it with food, some researchers suggest. Investigators said they found that taking Zytiga (abiraterone acetate) with a low-fat breakfast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2018 Category: General Medicine Source Type: news

Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (abiraterone acetate) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2018 Category: Drugs & Pharmacology Source Type: news

ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
New indication for ZYTIGA® in combination with prednisone provides treatment option for patients with metastatic high-risk castration-sensitive prostate cancer Findings from pivotal Phase 3 LATITUDE clinical trial data demonstrated statistically sig... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, ZYTIGA, abiraterone, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2018 Category: Pharmaceuticals Source Type: news

ZYTIGA ® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on Apalutamide (ARN-509), ZYTIGA ® (abiraterone acetate) and Erdafitinib
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 25, 2018 Category: Pharmaceuticals Source Type: news

U.S. Court Invalidates Patent on J & J Cancer Drug Zytiga U.S. Court Invalidates Patent on J & J Cancer Drug Zytiga
A U.S. administrative court on Wednesday invalidated a Johnson& Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

U.S. court invalidates J & J cancer drug patent, hitting UK's BTG
NEW YORK (Reuters) - A U.S. administrative court invalidated a Johnson& Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc . (Source: Reuters: Health)
Source: Reuters: Health - January 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson Issues Statement on ZYTIGA ® Inter Partes Reviews
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 18, 2018 Category: Pharmaceuticals Source Type: news

U.S. court invalidates patent on J & J cancer drug Zytiga
NEW YORK (Reuters) - A U.S. administrative court on Wednesday invalidated a Johnson& Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions. (Source: Reuters: Health)
Source: Reuters: Health - January 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Concern Over Adverse Events in Prostate Cancer Trial Concern Over Adverse Events in Prostate Cancer Trial
A phase 3 trial investigating the addition of radium-223 to abiraterone acetate plus steroid has been stopped after reports of fractures and deaths.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

30.11.17: Not intended for U.S. and UK Media
Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded earlyDecision follows a recommendation from an Independent Data Monitoring Committeemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 30, 2017 Category: Pharmaceuticals Source Type: news

Abiraterone Improves Outcomes in Metastatic Prostate Cancer Abiraterone Improves Outcomes in Metastatic Prostate Cancer
Abiraterone acetate plus prednisone improves outcomes in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC), regardless of baseline risk factors, according to results from the phase 3 COU-AA-302 study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - October 10, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA ® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Filing Supported by Data from Pivotal LATITUDE Trial Evaluating ZYTIGA ® in Combination with Prednisone and Androgen Deprivation Therapy (ADT) (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 14, 2017 Category: Pharmaceuticals Source Type: news

New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 8, 2017 Category: Pharmaceuticals Source Type: news

New Data Change Metastatic Prostate Cancer Treatment Paradigm New Data Change Metastatic Prostate Cancer Treatment Paradigm
Dr Chodak reviews results of the LATITUDE trial, which compared ADT alone versus ADT with abiraterone acetate plus prednisone.Medscape Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2017 Category: Consumer Health News Tags: Urology Commentary Source Type: news

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
The NDA contains data to support approval for YONSA, (abiraterone acetate) ultramicrosize tablets, for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Churchill Pharmaceuticals also announces positive results from the pivotal ST... Biopharmaceuticals, Oncology, FDA Churchill Pharmaceuticals, YONSA, abiraterone, Prostate Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 20, 2017 Category: Pharmaceuticals Source Type: news

Drugs Score Big Wins Against Lung, Prostate, Breast Cancers
CHICAGO (AP) — Drugs are scoring big wins against common cancers, setting new standards for how to treat many prostate, breast and lung tumors. There’s even a “uni-drug” that may fight many forms of the disease. What’s striking: The drugs are beneficial in some cases for more than a year, much longer than the few months many new drugs provide. Here are highlights from the world’s largest cancer meeting, the American Society of Clinical Oncology conference in Chicago. PROSTATE CANCER Janssen Biotech’s Zytiga improved survival and delayed cancer growth for 18 months when added to sta...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 5, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Breast Cancer Health News Prostate Cancer Source Type: news

Early use of J & J's Zytiga extends prostate cancer survival
CHICAGO (Reuters) - Adding Johnson& Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Abiraterone/ADT Combo Increased Prostate Cancer Survival
Combined therapy with abiraterone acetate/prednisone plus ADT significantly improved overall survival and radiographic progression-free survival among men with metastatic hormone-naive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Prostate Cancer News Source Type: news

Drug Extends Lives of Patients With Advanced Prostate Cancer: Studies
SATURDAY, June 3, 2017 -- Men with advanced prostate cancer might be able to avoid chemotherapy by taking an additional anti-testosterone pill along with standard hormone therapy, a pair of new clinical trials show. The drug, abiraterone (Zytiga),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 3, 2017 Category: General Medicine Source Type: news

Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Na ïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 3, 2017 Category: Pharmaceuticals Source Type: news

Study shows early Zytiga use improves prostate cancer survival
CHICAGO (Reuters) - Adding Johnson& Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the risk of death for men newly diagnosed with prostate cancer that had spread to other parts of the body, according to new trial results. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Churchill Pharmaceuticals Announces Submission of NDA for Yonsa (abiraterone acetate) Novel Oral Formulation of Prostate Cancer Treatment
King of Prussia, PA., May 23, 2017 Churchill Pharmaceuticals, LLC (Churchill) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Yonsa (abiraterone acetate), an improved ultramicrosize... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 24, 2017 Category: Drugs & Pharmacology Source Type: news

ASCO 2017: Janssen to Present 19 Abstracts in Prostate Cancer and a Spectrum of Blood Cancers; Includes Data on Abiraterone Acetate, Daratumumab and Ibrutinib
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 18, 2017 Category: Pharmaceuticals Source Type: news

Trial: Abiraterone acetate responses even after initial hormone therapy failure
(University of Colorado Anschutz Medical Campus) Results of a 40-person clinical trial published in JAMA Oncology show that 13 percent of prostate cancer patients deemed 'hormone refractory' did, in fact, have strong responses to treatment with the next-generation hormonal drug abiraterone acetate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2017 Category: Global & Universal Source Type: news

Low-Fat Meal May Boost Costly Cancer Drug
FRIDAY, Feb. 17, 2017 -- Eating a low-fat meal when taking an expensive prostate cancer drug can cut the cost of the drug by three-quarters, a new study indicates. " We know this drug [Zytiga] is absorbed much more efficiently when taken with food, " ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 17, 2017 Category: Journals (General) Source Type: news

Zytiga (Abiraterone Acetate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 31, 2016 Category: Drugs & Pharmacology Source Type: news

Abiraterone Acetate in Metastatic CRPCAbiraterone Acetate in Metastatic CRPC
Abiraterone acetate therapy for metastatic castration-resistant prostate cancer has shown efficacy in clinical trials, but are those same results achieved in real-world clinical practice? BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Greater survival benefit shown in men with early and less aggressive mCRPC treated with Zytiga® plus prednisone
Janssen announced that data from a post-hoc analysis of the Phase III COU-AA-302 trial showed that ZYTIGA® plus prednisone provided an 11.8 months overall survival benefit, compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 14, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology Patient care advanced prostate cancer COU-AA-302 trial European Association of Urology Latest News mCRPC Zytiga Source Type: news